Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Mar 7;120(10):e2300988120.
doi: 10.1073/pnas.2300988120. Epub 2023 Feb 27.

Rare disease informs mechanism and possible treatment of statin-associated myopathy

Tamar Harel  1   2
Affiliations
Comment

Rare disease informs mechanism and possible treatment of statin-associated myopathy

Tamar Harel. Proc Natl Acad Sci U S A. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares no competing interest.

Figures

Fig. 1.
Fig. 1.
HMG-CoA reductase dysfunction by genetic, environmental, or autoimmune mechanisms. A biallelic variant in HMGCR, encoding the rate-limiting enzyme in cholesterol synthesis known as HMG-CoA reductase, is herein reported to cause limb-girdle muscular dystrophy (LGMD). The disease responds to treatment with a derivative of mevalonate, which is the downstream metabolite of HMG-CoA reductase. The Middle panel indicates the effect of statins as inhibitors of HMG-CoA reductase, with resultant myopathy as a common adverse effect. The Right panel demonstrates anti-HMGCR myositis, which can result from auto-antibodies to HMG-CoA reductase triggered by or independent of statin exposure.
See this image and copyright information in PMC

Comment on

References

    1. Adhyaru B. B., Jacobson T. A., Safety and efficacy of statin therapy. Nat. Rev. Cardiol. 15, 757–769 (2018). - PubMed
    1. Cohen J. D., Brinton E. A., Ito M. K., Jacobson T. A., Understanding statin use in America and gaps in patient education (USAGE): An internet-based survey of 10,138 current and former statin users. J. Clin. Lipidol. 6, 208–215 (2012). - PubMed
    1. Ferriz Vivancos J., Sánchez M. F., Timoneda P. T. T., Benito G. M., Anti-HMGCR myopathy without exposure to statins: A case report. EJIFCC. 33, 342–349 (2022). - PMC - PubMed
    1. Yogev Y., Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone. Proc. Natl. Acad. Sci. U.S.A. 120, e2217831120 (2023). - PMC - PubMed
    1. Grable-Esposito P., et al. , Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. 41, 185–190 (2010). - PubMed

MeSH terms

Substances